NCT06585761

Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: Kafrelsheikh University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to explore the effect of SGLT2i on the levels of cardiac biomarkers, inflammatory and stress markers in Egyptian heart failure patients to provide a better understanding of mechanism that might assist in tailoring treatment strategies in patients with various forms of HF especially in Egyptian population. Also understand how biomarkers may be employed to predict risk in patients receiving SGLT2i or identification of those who may derive the most benefit from SGLT2i in the means of individualized medicine.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	SGLT2 inhibitor	patients with HF are subjected to regular dose of SGLT2I member according to patient status.
DEVICE	echo cardiogram	the patients are subjected to ECHO to determine their EF prior to and post the study

Timeline

• Start date: 2024-02-15
• Primary completion: 2025-06-30
• Completion: 2025-06-30
• First posted: 2024-09-05
• Last updated: 2024-09-05

Locations

1 site across 1 country: Egypt

Regulatory

• FDA-regulated device study